Forskning ved Københavns Universitet - Københavns Universitet


Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM). GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety and slows gastric emptying. This review evaluates the phase III trials for all approved GLP-1 RAs and reports that all GLP-1 RAs decrease HbA1c, fasting plasma glucose, and lead to a reduction in body weight in the majority of trials. The most common adverse events are nausea and other gastrointestinal discomfort, while hypoglycaemia is rarely reported when GLP-1 RAs not are combined with sulfonylurea or insulin. Treatment options in the near future will include co-formulations of basal insulin and a GLP-1 RA.

TidsskriftExpert Review of Clinical Pharmacology
Udgave nummer2
Sider (fra-til)241-65
Antal sider25
StatusUdgivet - 2016

ID: 176702269